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Abstract ObjectivesHerpessimplexvirustype1andtype2
(HSV-1 and HSV-2) are both highly prevalent. The rate of
genitalHSV-1transmissionisreportedlyincreasingovertime.
HSV-2 is considered to be an important risk factor for HIV
transmission. We therefore studied changes in the HSV-1 and
HSV-2 prevalencein a largecohort ofmenwho have sex with
men(MSM)overa20-yeartimeperiod.MethodsAmong1847
HIV-infected and HIV-uninfected MSM participating in the
Amsterdam Cohort Studies, seroprevalence of HSV-1 and
HSV-2 was determined and prevalence rate ratios (PRR) and
95% conﬁdence intervals were calculated. Results Between
1984 and 2003 the HSV-1 and HSV-2 prevalence decreased
among HIV-uninfected MSM (P\0.001), but remained sta-
ble among HIV-infected MSM. HSV-1 prevalence increased
among men with at least 200 sexual partners over lifetime
(PRR: 1.49, P\0.001). The association between HIV infec-
tion and HSV-2 became stronger over time (PRR: 3.45,
P\0.001).ConclusionsSeroprevalence of HSV-1 and HSV-
2 remained high among HIV infected MSM from 1984 to
2003.The association ofHIV andHSV-2 increased during the
HIV epidemic. Since the proportion of sexual transmission of
HSV-1 is rising, it is important to study the potential role of
HSV-1 as risk factor for HIV acquisition.
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Introduction
Herpes simplex virus type 1 (HSV-1) is widespread in the
general population, while herpes simplex virus type 2
(HSV-2) is more restricted to risk groups such as men who
have sex with men (MSM). HSV-1 prevalence is around
70% in the general population [1, 2]. Transmission usually
occurs during childhood through oral contact and normally
causes oropharyngeal infection. Childhood HSV-1 trans-
mission has declined in industrialised countries, resulting
in a lower prevalence of HSV-1 and leaving a larger
population of adolescents at risk for sexual transmission of
HSV-1. Earlier studies have reported sexually related risk
factors for HSV-1 infection in women [3]. Among those
persons attending the STD clinic and blood donors, HSV-1
infection is associated with younger age of ﬁrst intercourse
[4]. However, less is known about sexually related risk
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infection is usually transmitted sexually and is considered
as a marker for sexual risk behaviour in populations [6]. In
HIV-infected MSM, the prevalence of HSV-2 is as high as
61% [1], while being 15–25% in the general population [7,
8]. HSV-2 is a risk factor for HIV acquisition, especially in
the African setting [9] and in MSM [10]. HSV-2 infected
persons are more susceptible for HIV [11, 12]. Moreover,
HIV-infected persons are more likely to have subclinical
reactivation of HSV-2 and are therefore more likely to
transmit the virus [13].
We previously demonstrated a decline in the prevalence
of HSV-2 among MSM in Amsterdam between 1984–
1997, which could be explained by a decrease in sexual
risk behaviour [5]. However, in the second half of the
1990s their sexual risk behaviour increased after effective
HIV therapy became generally available. This may have
caused an increase in the prevalence of HSV-2 and possi-
bly also in HSV-1 since 1996.
We here studied the trend in HSV-1 and HSV-2 prev-
alence among homosexual men over a 20-year time period
(1984–2003) and whether risk factors for infection changed
during this period.
Methods
Study population
In 1984 an open and prospective cohort study on HIV
seroconversion and AIDS among sexually active HIV-
negative and positive homosexual men was started. The
Amsterdam Cohort Study (ACS) is still ongoing, although
entry criteria with respect to HIV status and age have
changed over time. From 1984 until May 1985, both HIV-
positive and HIV-negative men were included. From May
1985 until February 1988, only HIV-negative men were
allowed in the study. From February 1988 through 1994,
HIV-positive and HIV-negative men could enter the study,
but since 1995, they must be £30 year of age.
At an ACS visit, a standardised questionnaire is
administered regarding demographics, sexual behaviour,
and medical history for sexually transmitted infections
(STI). Blood samples are collected for immunologic and
virologic testing and for storage. For this study, stored sera
(collected at the ﬁrst cohort visit) taken from ACS partic-
ipants with at least two cohort visits (1847/2100 (88%))
were tested for HSV-1 and HSV-2.
Laboratory methods
Sensitive and speciﬁc FDA approved serological assay for
HSV-1&2 was used (HerpeSelect by FOCUS technologies,
USA). Its manufacturer recommends an index value[1.1
as positive. However, there is evidence that using this cut-
off value in HSV-2 studies yields a high rate of false
positive results in populations with multiple infections,
such as those in Africa [14]. Raising the positive cut-off
will increase the speciﬁcity [14]. Since the optimal cut-off
for our target population has not been established, 100
samples with results in the range of 0.9 and 3.5 were re-
tested with a highly speciﬁc Western blot. HSV-2 ELISA
and Western blot results were concordant for 80/100
samples. The proportion of samples that were positive with
both ELISA and Western blot increased with increasing
index value (Fig. 1). Based on these results, we consider a
cut-off value of ‡2.1 as being positive and an index value
\2.1 is classiﬁed as negative. The HSV-2 index value\2.1
had 36% concordance with Western blot results, while the
HSV-2 index value of ‡2.1 showed 93% concordance.
There were no differences in Western blot outcomes
between HIV-infected and HIV uninfected MSM.
Blood samples were tested for HSV-1 and HSV-2 at the
Public Health Laboratory of the Health Service of
Amsterdam. The Western blot was conducted at the Insti-
tute for Pathology and Medical Research (ICPMR) in
Sydney, Australia. Blood samples are also tested for HIV
antibodies by enzyme linked immunosorbent assay
(ELISA) (Abbot Laboratories, North Chicago, Illinois,
USA; Vironostika, Organon, Teknika, Boxtel, the Nether-
lands), and when positive, are conﬁrmed by Western blot.
Variables and statistical analyses
The statistical analyses were based on the data collected at
entry of the cohort. Variables used in this study were cal-
endar year of ACS entry, HIV-status, age, nationality,
education, age of ﬁrst homosexual contact, lifetime sexual
0
5
0 1
5 1
0 2
5 2
0 3
5 . 3 - 0 . 3 9 . 2 - 5 . 2 4 . 2 - 0 . 2 9 . 1 - 5 . 1 4 . 1 - 1 . 1 1 . 1 - 9 . 0
HSV -2 indez value
N
u
m
b
e
r
 
o
f
 
s
a
m
p
l
e
s
Negative by Western blot
Positive by Western blot
Fig. 1 Comparison of HSV-2 serology by ELISA and Western blot.
100 samples were tested with HSV-2 ELISA and re-tested with the
Western blot to identify discrepancies between the two assays
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123partners, and self-reported history of syphilis and gonor-
rhoea in the past 5 years.
Variables concerning sexual practices included orogenital,
anogenital and oroanal contact in the prior 6 months. Some
changes in the questions were made in the questionnaires
between 1984 and 2003 regarding the sexual practices. Oro-
anal contact was not asked for from 1889 to 1994, resulting in
approximately 25% missing values on this variable. From
1995 onward, the most important difference was that oro-
genital contact with ejaculation was asked, while in the
previous years orogenital contact in general was asked. The
percentage of participants not having orogenital contact was
somewhat higher for the years 1995 and 1996.
The prevalence of HSV-1 and 2 at the ACS entry was
determined andrisk factors for HSV-1 and 2 were assessed by
calculating prevalence rate ratios (PRR), with their 95% con-
ﬁdence interval (CI). Odds ratios could not be interpret as
relativerisks,sincetherareeventassumptionwasnotreached.
Therefore PRR’s were directly estimated, using a modiﬁed
Poisson regression approach [15]. This approach provided a
correctly estimated standard error for the estimated relative
risk.SinceinclusioncriteriawithrespecttoageandHIV-status
changed over time, all risk factor analyses were adjusted for
ageandHIV-status.Variablesthatwerestatisticallysigniﬁcant
were included in the multivariate model, using a stepwise
forward approach forcing age and HIV-status in the model.
We tested whether risk factors changed over time by
testing for interaction between variables under investiga-
tion and calendar time in the multivariate model. Calendar
time therefore was categorised as 1984–1986, 1987–1991,
1992–1996, 1997–2003.
Confounding was deﬁned to be present when the included
variable caused a change of the prevalence ratio by more than
10%. Interaction was deﬁned to be present when the addition
of an interaction term improved the original model and the P-
value was\10%. Statistical signiﬁcance was deﬁned as a P-
value\0.05. To reduce residual confounding when measur-
ing the association between HSV and sexual practices, three
variables measuring sexual practices over the prior 6 months
were included in themodel at the same time, together with the
lifetime sexual partners. We modelled time trends in the
HSV-1 and 2 prevalence with calendar time as a continuous
variable using restricted cubic splines with four knots,
resulting in a smoothly varying curve.
For 77 MSM the HSV-1 index value was missing and 91
MSM had a missing HSV-2 index value. Participants with a
missing index value for both HSV-infections were not
included in the analyses. MSM with a missing index value for
one HSV-infection, but with a known HSV status of the other
HSV-infection were included in the analyses for the known
HSV serostatus.
Finally, sensitivity analyses for HSV-2 were conducted
by using the cut-off value of 1.1, as recommended by the
manufacturer and by using the cut-off value of 3.5,
excluding those with an index value in the grey area
(between 0.9–1.1 and 0.9–3.5). However, time trends in
prevalence and risk factors found were comparable to when
2.1 was the cut-off value (data not shown).
Results
General characteristics
Between 1984 and 2003, a total of 1847 MSM had at least
two visits. General characteristics of the total study group
are presented in Table 1. Of the 1847, 1207(65%) MSM
were HSV-1 antibody positive, while 759/1847(41%) of
the men were HSV-2 antibody positive. Of the total group,
558(30%) were positive for both. Participants were pre-
dominantly of Dutch nationality (86%) and had a median
age of 29 years (interquartile range: 25–36).
Prevalence of HSV-1 and HSV-2 over time
There was an overall decline in the prevalence of both
HSV-1 and 2 between 1984 and 2003 (Tables 1, 2). To
investigate time trends in HSV seroprevalence we included
an interaction term between time and HIV-status (Fig. 2a,
b). Among HIV-negative MSM, the HSV-1 prevalence
decreased signiﬁcantly over time, P\0.001 (Fig. 2a).
Among HIV-positive MSM, the HSV-1 prevalence
remained stable over time, P = 0.35(Fig. 2a).
The HSV-2 prevalence signiﬁcantly decreased among
HIV-negative men, P\0.001(Fig. 2b). Results from the
regression models showed that, after adjustment for chan-
ges in age, nationality, education and changes in sexual risk
behaviour, the decline in HSV-2 prevalence among HIV
negative MSM remained signiﬁcant (PRR adjusted 0.92,
P\0.001). In contrast, the HSV-2 prevalence remained
stable over time for men infected with HIV (P = 0.12).
Again, this result was observed after controlling for age,
demographic characteristics and sexual behaviour.
Risk factors
Risk factors for HSV-1 and HSV-2 infection, adjusted for
age and HIV-status, are presented in Table 1.
In the ﬁnal model calendar year, HIV-status, nationality,
and number of lifetime sexual partners remained indepen-
dent predictors for HSV-1 infection (Table 2). For HSV-2
infection, earlier year of study entry, positive HIV-status,
HSV-1 co-infection, a history of syphilis and sexual
behaviour remained independent predictors (Table 2).
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123Changing risk factors over time
Different interaction terms were included in the model. It
appeared that the effect of calendar year differed between
HIV-infected and HIV-uninfected MSM for both HSV-1
and HSV-2.
As shown in Fig. 2a, the association between HIV and
HSV-1 became stronger over time. This was due to the
Table 1 Demographic and sexual characteristics of 1847 homosexual men, for the total study group, and for HSV-1-infected participants and
HSV-2-infected participants separately, between 1984 and 2003, with the prevalence ratios for HSV-1 and HSV-2 with their 95% conﬁdence
intervals
a
Characteristics Total HSV-1-
infection
PRR
(95% CI)
Overall
P-value
HSV-2-
infection
PRR
(95% CI)
Overall
P-value
Total 1847 1207 (65) 759 (41)
Year of study entry \0.0001 \0.0001
1984–1986 943 675 (72) 1 461 (49) 1
1987–1991 165 113 (68) 0.87 (0.78–0.97) 92 (56) 0.84 (0.72–0.98)
1992–1996 222 138 (43) 0.88 (0.79–0.96) 80 (36) 0.66 (0.56–0.77)
[1997 517 281 (54) 0.76 (0.70–0.84) 126 (24) 0.47 (0.40–0.55)
Index value
\0.9 – 535 853
0.9–1.1 – 29 32
1.1–2.1 – 100 112
‡2.1 – 1107 759
Missing 77 91
Age \0.0001 \0.0001
\30 years 1002 570 1 252 1
‡30 years 845 637 1.20 (1.13–1.29) 507 1.98 (1.75–2.23)
Nationality: 0.006 0.62
Dutch 1586 947 (60) 1 615 (39) 1
Northern/central Europe 116 72 (62) 1.04 (0.92–1.18) 54 (47) 1.08 (0.90–1.38)
Non-European 145 117 (81) 1.17(1.07–1.28) 75 (52) 1.04 (0.91–1.23)
Education 0.005 0.007
Low 96 77 (80) 1 57 (59) 1
Middle 669 408 (61) 0.85 (0.76–0.95) 239 (36) 0.72 (0.59–0.87)
High 971 574 (59) 0.81 (0.73–0.81) 387 (40) 0.79 (0.66–0.94)
Missing 115 77 (67) 54 (47)
Sexual partners in lifetime
1–20 860 497 (58) 1 \0.0001 277 (32) 1 0.51
21–200 531 360 (68) 1.12 (1.04–1.22) 212 (40) 2.30 (0.93–1.21)
[200 443 339 (77) 1.24 (1.15–1.34) 262 (59) 1.07 (0.95–1.20)
Age of ﬁrst homosexual contact
(median, IQR)
18 (15–20) 17 (15–20) 1.01(1.01–1.02)^ \0.0001 17 (15–20) 0.99 (0.99–1.01)
c 0.32
HSV co-infection 568 568 1.29 (1.14–1.47) \0.0001 568 1.167 (1.08–1.24) \0.0001
HIV infection (%) 513 367 (72) 1.11 (1.03–1.18) 0.007 312 (61) 1.12 (1.00–1.24) 0.05
History of gonorrhoea in the past 5 years 1053 666 (63) 0.88 (0.83–0.93) 0.0005 424 (40) 0.88 (0.79–0.97) 0.02
History of syphilis in the past 5 years 278 219 (79) 1.15 (1.07–1.24) 0.001 197 (71) 1.51 (1.36–1.69) \0.0001
Orogenital contact in the past 6 months
b 1363 892 (65) 0.99 (0.82–1.22) 0.46 565 (41) 0.69 (0.55–0.87) 0.01
Anogenital contact in the past 6 months
b 1222 819 (67) 1.11 (1.14–1.60) 0.002 551 (45) 1.36 (1.16–1.60) 0.0002
Oroanal in the past 6 months
b 1081 700 (65) 1.00 (0.91–1.09) 0.99 438 (41) 0.98 (0.85–1.12) 0.80
a Since ACS inclusion criteria have changed over times all analyses were adjusted for age (per 10-year increase) and HIV status at cohort entry
b Analyses are also adjusted for the sexual techniques and number of partners to exclude residual confounding
c Per 10 year of increase
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123decline in HSV-1 prevalence over time among HIV-nega-
tive MSM but not among HIV-positive MSM (Fig. 2a).
For HSV-2 the association with HIV infection increased
with calendar year and was highest after 1996 (Fig. 2b).
For HSV-1, also the effect of calendar time differed with
respect to nationality, number of lifetime sexual partners,
and with HSV-2 co-infection. As shown by the regression
model, a decrease in HSV-1 infection over time was
Table 2 Multivariate model of risk factors associated with HSV-1 infection
HSV-1 Overall P-value
(a) HSV-1 infection
Year of study entry \0.0001
1984–1986 1
1987–1991 0.91 (0.70–1.18)
1992–1996 0.83 (0.66–1.02)
[1997 0.75 (0.63–0.90)
Age 1.13(1.07–1.18) \0.0001
HIV serostatus
Negative 1 0.01
Positive 1.10 (1.02–1.18)
Nationality
Dutch 1 0.0006
Northern or Central European 1.05 (0.92–1.20)
Non European 1.62 (1.12–1.36)
Education 0.25
Low 1
Middle 0.90 (0.79–1.00)
High 0.84 (0.76–1.06)
Sexual partners in lifetime
1–20 1 0.003
21–200 1.13 (1.05–1.25)
[200 1.13 (1.04–1.23)
History of Gonorrhoea in the past 5 years 0.97 (0.90–1.03) 0.11
History of Syphilis in the past 5 years
Orogenital contact in the past 6 months 1.12 (0.88–1.43) 0.42
Anogenital contact in the past 6 months 1.08 (0.97–1.20) 0.20
Oroanal contact in the past 6 months 1.02 (0.70–1.13) 0.81
HSV-2 Overall P-value
(b) HSV-2 infection
Year of study entry \0.0001
1984–1986 1
1987–1991 0.86 (0.70–1.06)
1992–1996 0.58 (0.48–0.71)
[1997 0.47 (0.39–0.56)
HIV serostatus
Negative 1 \0.0001
Positive 1.50 (1.37–1.68)
HSV coinfection 1.15 (1.02–1.30) 0.02
History of Syphilis in the past 5 years 1.21 (1.08–1.36) 0.001
Orogenital contact in the past 6 months 0.69 (0.56–0.84) \0.0001
Anogenital contact in the past 6 months 1.20(1.08–1.42) 0.02
Oroanal contact in the past 6 months 1.00(0.87–1.15) 0.72
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123observed only among MSM with Dutch or Northern/Cen-
tral-European nationality. The association between HSV-1
and having non-European origin became stronger over
time. The adjusted PRR was 1.08 (P = 0.3) before 1986
and the adjusted PRR became 1.58 (P\0.0001) for the
time period after 1996.
Also the association between HSV-1 and a higher
number of lifetime sexual partners became stronger after
1996. Figure 3a shows the prevalence of HSV-1 infection
over time according to the number of sexual lifetime
partners. A decrease in the HSV-1 prevalence was seen
among MSM with fewer than 21 partners (P\0.0001),
while among MSM with more than 200 partners, the HSV-
1 prevalence increased between 1988 and 2003 (P = 0.01).
For HSV-2, the effect of calendar time differed with
respect to the number of lifetime sexual partners and with
HSV-1 co-infection. A large number of lifetime partners
also was strongly associated with HSV-2. However, a
decrease in the HSV-2 prevalence was seen among all
categories of lifetime sexual partners (Fig. 3b), but this
decrease was stronger for MSM with fewer than 21 part-
ners and for those MSM with 21–200 partners.
Discussion
In the present study, we demonstrated an overall decrease in
HSV-1 and HSV-2 prevalence among HIV-negative MSM,
but not among HIV-positive MSM. In the 1984–2003 period,
the association between HSV-2 and HIV among MSM
became stronger over time, and HSV-1 prevalence increased
in highly sexually active HIV-negative MSM. To our
Fig. 2 (a) HSV-1 prevalence in the Amsterdam Cohort Study among
MSM, according to the HIV status (1 = HIV positive, 0 = HIV
negative) and the 95% conﬁdence interval. (b) HSV-2 prevalence in
the Amsterdam Cohort Study among MSM, according to the HIV
status (1 = HIV positive, 0 = HIV negative) and the 95% conﬁdence
interval
Fig. 3 (a) Prevalence of HSV-1 and the 95% conﬁdence interval over
time among HIV negative MSM, according to number of lifetime
sexual partners; 1 = 1–20, 2 = 21–200, 3[200 partners. (b) Preva-
lence of HSV-2 and the 95% conﬁdence interval over time among
HIV negative MSM, according to number of lifetime sexual partners;
1 = 1–20, 2 = 21–200, 3[200 partners
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123knowledge, this is the ﬁrst study based on almost 20 years of
HSV-1 and HSV-2 prevalence data among MSM.
The decrease seen in the seroprevalence of HSV-1 and
HSV-2 over time, could not be explained by changes in
demographic characteristics or sexual behaviour. The
decrease in HSV-1 is likely to reﬂect a decrease in child-
hood transmission by the oropharyngeal contact of HSV-1.
Since fewer individuals are infected in childhood with
HSV-1, there is a growing population of persons at risk at
the time they become sexually active, resulting in a larger
proportion of sexual transmission of HSV-1. Two risk
factors for HSV-1 infection that could be important in its
sexual transmission were identiﬁed by this study. First,
HIV infection is associated with HSV-1 seropositivity.
Second, the prevalence of HSV-1 was higher among highly
sexual active MSM (at least 200 lifetime sexual partners).
An association also shown earlier by others [3].
HIV infection in this respect may reﬂect an epidemio-
logical marker for sexual risk behaviour for HSV-1
transmission. HSV-1 prevalence did not decrease in those
infected with HIV, and we consider that genital HSV-1
infection has a growing role in the acquisition of HIV.
Likewise, HSV-2 prevalence did not decline over time
among those infected with HIV, whereas a decline was
noted among HIV uninfected MSM.
Although HSV-2 is sexually transmitted, we did not ﬁnd
an association between a higher number of lifetime part-
ners and HSV-2 infection. HSV-2 was also highly
prevalent among MSM with 1–20 lifetime partners. Mainly
between 1984 and 1995, there were no major differences in
the proportion of MSM infected with HSV-2. This suggests
that HSV-2 is highly sexual transmissible and when having
a low number of life time partner the risk of receiving a
HSV-2 infection is still very high.
The results of this study show a protective effect of
orogenital contact for HSV-2 infection, which might be
explained by the fact that anogenital contact is a stronger
predictor for HSV-2 infection. All variables measuring
sexual practices are included in the analyses at the same
time. Since most MSM practised all the techniques during
the same time period these practices could not be analysed
as independent risk factors. The stronger effect of ano-
genital contact might have overruled the effect of
orogenital contact, resulting in a protective effect of oro-
genital contact.
The overall prevalence of HSV-2 in this study is similar
to that among MSM in San Francisco in 1989, but higher
than the prevalence found in more recent studies in the US
[16–18]. The lower prevalence in those more recent studies
probably reﬂects the decline in HSV-2 prevalence over
time, as found in our study.
Russell et al., found high prevalence rates of HSV-2
among HIV-infected MSM in Australia [1]. The HSV-2
seroprevalence was more than twice as high as among
HIV-uninfected MSM; there was no signiﬁcant difference
in HSV-1 prevalence between HIV-infected and HIV-
uninfected MSM.
Several epidemiological studies have described an
association between HIV and HSV-2 [10]. HSV-2 is
recognised as a risk factor for HIV acquisition in MSM. In
addition, HSV-2 may up-regulate HIV and increase local
HIV replication on mucosal surfaces, leading to an
increased risk of HIV transmission. Our study is the ﬁrst to
show an increase in the association between HSV-2 and
HIV since 1996, suggesting that HSV-2 may play a
growing role in driving the HIV epidemic in MSM. If this
is the case, prevention of HSV-2 may well contribute to the
prevention of HIV among highly sexually active MSM.
Although serological screening for HSV-2 among MSM is
still under debate, the increasing association between HSV-
2 seropositivity and HIV is an argument in its favour.
Several reasons against screening have been raised, such as
the lack of a reliable serological test. We are aware of the
low speciﬁcity of the various HSV-2 serological assays.
However, these serological assays might be useful as a
screening tool, when used with an increased cut-off value
less individuals will be classiﬁed as false positive. A sec-
ond argument against serological screening is that HSV-2
infection is largely asymptomatic and condom use appears
only partially protective against HSV transmission. These
factors complicate the prevention of HSV-2 and genital
HSV-1 infection. However, it has been shown that half of
the patients, initially unaware of their HSV-2 infection are
able to recognise symptoms after being educated to do so
[19]. Also, knowledge of the HSV-2 status of a sexual
partner has been associated with a reduced risk of HSV-2
transmission [20]. Antiviral drugs used as suppressive
therapy will lower the frequency of recurrences by 70–80%
[21, 22]. A combined approach of offering serological
screening to highly sexual active MSM together with
encouraging condom use to reduce the risk of HSV trans-
mission and using suppressive therapy among those with
recurrent lesions might eventually play an effective part in
controlling the HIV epidemic among MSM.
One limitation of our study is its cross-sectional design.
As a consequence, we cannot reveal the relation between
HIV and HSV infection, being unable to determine which
occurredﬁrst.As bothHIVandHSVaresexuallytransmitted
diseases, their association may well reﬂect shared sexual
behavioural practices leading to transmission as well as a
biological relation. Longitudinal studies, in which incident
HIV and HSVcases are capturedare therefore neededto give
more insight into the relationship between HIV and HSV as
affected by changes in sexual risk behaviour.
The results of this study have two implications for HIV
and HSV research among highly sexually active MSM.
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123First, it appears that HSV-2 and HIV are now more
strongly related than in the early days of the HIV epidemic.
As a vaccine against HSV-2 for MSM is not yet available, a
determination of the extent to which the prevention of
HSV-2, specially aimed for MSM at high risk for HIV, can
contribute to controlling the HIV epidemic is needed.
Second, since the extent of sexual transmission of HSV-1 is
rising, we need to clarify its potential role as a risk factor
for HIV acquisition in longitudinal studies.
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